Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Clinical Immunology · CTLA4 Haploinsufficiency

Long-Term Health: Monitoring, Risks, and Warning Signs

At a Glance

CTLA4 haploinsufficiency requires individualized long-term monitoring because immune dysfunction can cause serious infections, low blood counts, viral reactivation, organ problems, and higher lymphoma or gastric cancer risk. Urgent symptoms need prompt medical evaluation.

Living with CTLA4 haploinsufficiency (CHAI) means transitioning into a phase of careful, long-term monitoring. Because this condition can affect multiple organs and carries an increased risk for certain complications, regular surveillance is the key to early detection and effective management.

When to Seek Urgent Medical Care

Because the immune system in CHAI is both overactive and under-protected, certain symptoms require immediate evaluation by your medical team or an emergency department.

Red Flags and Emergency Symptoms

  • Severe Infection: A fever meeting your individualized threshold (e.g., 38.0 °C / 100.4 °F or higher), shaking chills, or a sudden decline in energy. Because of immunodeficiency, infections can progress very quickly [1]. You should obtain an individualized written fever and after-hours action plan from your specialist.
  • Severe Bleeding or Bruising: Large, unexplained bruises, tiny red dots on the skin (petechiae), or bleeding from the gums or nose. This can signal a dangerous drop in platelets (thrombocytopenia) [2][3].
  • Neurological Changes: New or severe headaches, seizures, or weakness in a specific part of the body. These may indicate immune-mediated inflammation in the brain [4][5].
  • Digestive Crisis: Chronic diarrhea that becomes severe, leading to dizziness, dark urine, or extreme thirst (dehydration) [6][7].
  • Rapid Swelling: A sudden increase in the size of lymph nodes, or a feeling of extreme fullness or pain in the abdomen (which may be an enlarging spleen or liver) [8][1].

Understanding Malignancy Risks

Research has shown that people with CHAI have a higher risk of developing certain cancers compared to the general population. In a large international cohort study, approximately 12.9% of affected individuals developed a malignancy [8]. This is a cohort-specific proportion, not your personal lifetime risk.

  • Lymphoma: This is the most common cancer associated with CHAI. It is a cancer of the lymphatic system, often linked to impaired immune surveillance, chronic dysregulation, and sometimes treatment-related immunosuppression [8][1].
  • Gastric Cancer: There is an increased risk for stomach cancer, particularly in those who have chronic stomach inflammation (gastritis) or persistent digestive symptoms [8][7].
  • The Role of EBV: A very important finding is that many of these cancers (70% of the lymphomas and 60% of the gastric cancers in one study) are associated with the Epstein-Barr Virus (EBV) [8].

The Vital Importance of Viral Monitoring

Monitoring for EBV and CMV (Cytomegalovirus) is one of the most critical parts of your long-term care. While these are common viruses that many people carry without issue, they can “reactivate” in people with CHAI, especially when taking immunosuppressant medications like Abatacept or Sirolimus [8][1].

High levels of EBV in the blood (the “viral load”) can be clinically important and prompt closer evaluation, but it is not by itself a diagnosis of lymphoma [8]. Your doctor may order PCR tests (a sensitive blood test) to check these viral levels. However, testing frequency is individualized based on symptoms, treatments, and known risks, rather than a universal requirement [8][1]. Never interpret these results or alter medications without your treating team.

Routine Surveillance and Organ Monitoring

Your specialist will design an individualized monitoring plan based on your symptoms and known organ involvement.

  • Bloodwork: You will need regular Complete Blood Counts (CBC) to watch for low blood cells, and Immunoglobulin checks to ensure your antibody levels are sufficient [1].
  • Lung Monitoring: Since lung involvement can occur, doctors may use Chest CT scans, but due to radiation exposure risks, they are generally reserved for when you have symptoms or a specialist-defined indication, rather than routine scheduling [9].
  • Brain Monitoring: If neurological symptoms occur, a Brain MRI is used to look for inflammatory lesions [4]. Routine baseline MRIs for asymptomatic patients are individualized.
  • Gastric Surveillance: If you have persistent stomach pain or a history of severe gut issues, your team may recommend periodic endoscopy (using a small camera to look inside the stomach) to screen for early signs of cancer, though this is not a universal screening for all patients [7][10].

Maintaining a consistent relationship with an immunology center that specializes in immune dysregulation is the best way to ensure this monitoring happens on the right schedule for you [11].

Common questions in this guide

Why does CTLA4 haploinsufficiency require long-term monitoring?
CHAI can make the immune system overactive while also reducing protection against infections. It may affect several organs and raise the risk of blood-count problems, viral reactivation, lymphoma, and gastric cancer, so follow-up is tailored to the individual.
Which symptoms should prompt urgent care with CHAI?
Seek urgent evaluation for a fever at or above the threshold in your written plan, shaking chills, a sudden drop in energy, unusual bleeding or bruising, a new severe headache, a seizure, weakness in one part of the body, severe diarrhea with dehydration, or rapidly growing lymph nodes or abdominal swelling. Do not wait for routine follow-up if these occur.
Does a high EBV level mean that I have lymphoma?
No. A high EBV level in the blood can prompt closer evaluation, but it does not by itself prove lymphoma; your clinician may use symptoms, an examination, and other tests to decide what to do. Do not change medications based on the result without your treating team.
How often should EBV and CMV levels be checked in CHAI?
There is no single testing schedule for everyone with CHAI. The timing of EBV and CMV blood tests depends on symptoms, current medicines such as abatacept or sirolimus, and other risks identified by the specialist.
What tests are used for ongoing CHAI monitoring?
Follow-up may include complete blood counts, antibody-level tests, and blood tests that measure EBV and CMV levels. Chest CT, brain MRI, and stomach endoscopy are generally reserved for symptoms, a relevant history, or a specialist-defined reason rather than performed routinely for every patient.
What cancer risks are associated with CTLA4 haploinsufficiency?
CHAI is associated with an increased risk of lymphoma, the most common cancer reported with the condition, and with gastric, or stomach, cancer. Some cancers in reported groups were linked to EBV, but group-level percentages do not predict an individual person's lifetime risk.
When might I need a chest CT, brain MRI, or endoscopy?
A chest CT may be considered when lung symptoms or a specialist-defined indication is present, and a brain MRI is used when neurologic symptoms occur. Endoscopy may be recommended for persistent stomach symptoms or a history of severe gut problems, but these tests are not universal screening for everyone with CHAI.

Get notified when new evidence is published on Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.

    Schwab C, Gabrysch A, Olbrich P, et al.

    The Journal of allergy and clinical immunology 2018; (142(6)):1932-1946 doi:10.1016/j.jaci.2018.02.055.

    PMID: 29729943
  2. 2

    Pediatric-onset Evans syndrome: Heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations.

    Besnard C, Levy E, Aladjidi N, et al.

    Clinical immunology (Orlando, Fla.) 2018; (188()):52-57 doi:10.1016/j.clim.2017.12.009.

    PMID: 29330115
  3. 3

    A Rare Central Nervous System Involvement Due to CTLA-4 Gene Defect.

    Rovshanov S, Göçmen R, Barişta İ, et al.

    Noro psikiyatri arsivi 2022; (59(3)):248-252 doi:10.29399/npa.27900.

    PMID: 36160072
  4. 4

    Two neurologic facets of CTLA4-related haploinsufficiency.

    Ayrignac X, Goulabchand R, Jeziorski E, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2020; (7(4)) doi:10.1212/NXI.0000000000000751.

    PMID: 32499327
  5. 5

    Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.

    Coustal C, Goulabchand R, Labauge P, et al.

    Neurology 2023; (101(15)):e1560-e1566 doi:10.1212/WNL.0000000000207609.

    PMID: 37487754
  6. 6

    Efficacy of abatacept treatment in a patient with enteropathy carrying a variant of unsignificance in CTLA4 gene: A case report.

    Musabak U, Erdoğan T, Ceylaner S, et al.

    World journal of clinical cases 2023; (11(26)):6176-6182 doi:10.12998/wjcc.v11.i26.6176.

    PMID: 37731560
  7. 7

    Novel pathogenic CTLA4 missense variant associated with autoimmune enteropathy and systemic immune dysregulation.

    Zheng D, Tian C, Ye X, et al.

    Frontiers in immunology 2026; (17()):1855020 doi:10.3389/fimmu.2026.1855020.

    PMID: 42577265
  8. 8

    Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers.

    Egg D, Schwab C, Gabrysch A, et al.

    Frontiers in immunology 2018; (9()):2012 doi:10.3389/fimmu.2018.02012.

    PMID: 30250467
  9. 9

    Pulmonary manifestations of immune dysregulation in CTLA-4 haploinsufficiency and LRBA deficiency.

    Krone KA, Winant AJ, Vargas SO, et al.

    Pediatric pulmonology 2021; (56(7)):2232-2241 doi:10.1002/ppul.25373.

    PMID: 33710794
  10. 10

    A Patient with CTLA-4 Haploinsufficiency Presenting Gastric Cancer.

    Hayakawa S, Okada S, Tsumura M, et al.

    Journal of clinical immunology 2016; (36(1)):28-32 doi:10.1007/s10875-015-0221-x.

    PMID: 26644313
  11. 11

    Primary Immune Regulatory Disorders (PIRD): Tools for Diagnosis and Disease Activity Assessment to Guide Therapy.

    Oved JH, Torgerson TR, Chan AY

    The journal of allergy and clinical immunology. In practice 2026; (14(7)):1467-1474 doi:10.1016/j.jaip.2026.05.015.

    PMID: 42409454

This page is for informational purposes only and does not constitute medical advice. Your specialist should personalize fever instructions, surveillance, and interpretation of EBV, CMV, and other test results.